Home Cart Sign in  
Chemical Structure| 2070009-66-2 Chemical Structure| 2070009-66-2
Chemical Structure| 2070009-66-2

A-674563 HCl

CAS No.: 2070009-66-2

A-674563 HCl is a potent and selective Akt1 inhibitor with Ki of 11 nM.

Synonyms: A-674563 hydrochloride

4.5 *For Research Use Only !

Cat. No.: A976883 Purity: 99%

Change View

Size Price

US Stock

Global Stock

In Stock
1mg łËî¶ÊÊ Inquiry Inquiry
2mg łÍǶÊÊ Inquiry Inquiry
5mg łòó¶ÊÊ Inquiry Inquiry
10mg łÇÊǶÊÊ Inquiry Inquiry
50mg łÇÿ§¶ÊÊ Inquiry Inquiry
100mg łËÿó¶ÊÊ Inquiry Inquiry
250mg łÍ§ď¶ÊÊ Inquiry Inquiry

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1mg

    łËî¶ÊÊ

  • 2mg

    łÍǶÊÊ

  • 5mg

    łòó¶ÊÊ

  • 10mg

    łÇÊǶÊÊ

  • 50mg

    łÇÿ§¶ÊÊ

  • 100mg

    łËÿó¶ÊÊ

  • 250mg

    łÍ§ď¶ÊÊ

In Stock

- +

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support Online Technical Q&A
Product Citations

Alternative Products

Product Details of A-674563 HCl

CAS No. :2070009-66-2
Formula : C22H23ClN4O
M.W : 394.90
SMILES Code : N[C@@H](CC1=CC=CC=C1)COC2=CC(C3=CC4=C(C)NN=C4C=C3)=CN=C2.[H]Cl
Synonyms :
A-674563 hydrochloride
MDL No. :MFCD18711680

Safety of A-674563 HCl

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319
Precautionary Statements:P501-P270-P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313-P301+P312+P330

Related Pathways of A-674563 HCl

PI3K-AKT

Isoform Comparison

Biological Activity

Target
  • Akt1

    Akt1, Ki:11 nM

  • CDK2

    CDK2, Ki:46 nM

  • PKA

    PKA, Ki:16 nM

In Vitro:

Cell Line
Concentration Treated Time Description Reference
human iPSC-derived motor neurons 10 µM 4 hours Evaluate the neuroprotective effect of A-674563 against vincristine-induced neurotoxicity, results showed significant increase in neurite length. PMC11335239
human iPSC-derived sensory neurons 10 µM 4 hours Evaluate the neuroprotective effect of A-674563 against vincristine-induced neurotoxicity, results showed significant increase in neurite length. PMC11335239

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description Reference
Sprague-Dawley rats Acute liver failure induced by 90% partial hepatectomy Intraperitoneal injection 100 mg/kg Single dose, observed up to 24 hours To validate the effect of A-674563 on MSC transplantation in treating liver failure, it was found that A-674563 inhibited AKT activity, reversed the therapeutic effect of MSCs, and aggravated liver injury. PMC6468048
C57BL/6 mice myocardial ischemia/reperfusion injury model intravenous injection 100 mg/kg single dose, lasting 4 hours of reperfusion To evaluate the effect of A-674563 on the cardioprotective effects induced by high-concentration hydrogen (HCH), the results showed that A-674563 significantly inhibited the protective effects of HCH on myocardial ischemia/reperfusion injury. PMC5665927

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.53mL

0.51mL

0.25mL

12.66mL

2.53mL

1.27mL

25.32mL

5.06mL

2.53mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2
The prepared working fluid is recommended to be prepared now and used up as soon as possible in a short period of time. The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1

References

 

Historical Records

Categories